Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Has Consensus Target Price of $9.33 According to Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $9.33.

A number of research firms have weighed in on SANA. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Bank of America decreased their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th.

Sana Biotechnology Trading Down 3.3%

NASDAQ:SANA opened at $2.33 on Friday. Sana Biotechnology has a 1 year low of $2.32 and a 1 year high of $6.55. The firm’s fifty day simple moving average is $3.34 and its 200 day simple moving average is $3.30. The firm has a market capitalization of $697.51 million, a PE ratio of -3.07 and a beta of 2.18.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. As a group, analysts anticipate that Sana Biotechnology will post -0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alphabet Inc. bought a new position in shares of Sana Biotechnology in the second quarter valued at approximately $9,816,000. Bank of New York Mellon Corp acquired a new stake in Sana Biotechnology during the 2nd quarter valued at $1,667,000. Bank of America Corp DE acquired a new stake in Sana Biotechnology during the 2nd quarter valued at $20,062,000. Deutsche Bank AG bought a new position in Sana Biotechnology in the 2nd quarter valued at $2,251,000. Finally, Canada Pension Plan Investment Board bought a new position in Sana Biotechnology in the 2nd quarter valued at $35,662,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company’s approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana’s research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body.